Search Results - "COUTRE, S. E"

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia by RAWSTRON, A. C, VILLAMOR, N, EVAN, P. A. S, NATKUNAM, Y, COUTRE, S. E, AVERY, E. D, RASSENTI, L. Z, KIPPS, T. J, CALIGARIS-CAPPIO, F, KNEBA, M, BYRD, J. C, HALLEK, M. J, RITGEN, M, MONTSERRAT, E, HILLMEN, P, BÖTTCHER, S, GHIA, P, ZEHNDER, J. L, LOZANSKI, G, COLOMER, D, MORENO, C, GEUNA, M

“…The eradication of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) predicts for improved outcome. However, the wide variety of MRD…”
Get full text

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL by Brown, J R, Hillmen, P, O’Brien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, Byrd, J C

“…In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared…”
Get full text

Conversion of thrombin into an anticoagulant by protein engineering by Gibbs, C. S, Coutré, S. E, Tsiang, M, Li, W-X, Jain, A. K, Dunn, K. E, Law, V. S, Mao, C. T, Matsumura, S. Y, Mejza, S. Y, Paborsky, L. R, Leung, L. L. K

“…At sites of vascular injury, thrombin interacts with multiple procoagulant substrates, to mediate both fibrin clotting and platelet aggregation. But upon…”
Get full text

Protein Engineering Thrombin for Optimal Specificity and Potency of Anticoagulant Activity in Vivo by Tsiang, M, Paborsky, L. R, Li, W.-X, Jain, A. K, Mao, C. T, Dunn, K. E, Lee, D. W, Matsumura, S. Y, Matteucci, M. D, Coutré, S. E, Leung, L. L. K, Gibbs, C. S

“…Previous alanine scanning mutagenesis of thrombin revealed that substitution of residues W50, K52, E229, and R233 (W60d, K60f, E217, and R221 in…”
Get full text

FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2 by Coutre, S. E., Barr, P. M., Owen, C., Robak, T., Tedeschi, A., Bairey, O., Burger, J. A., Hillmen, P., Devereux, S., Grosicki, S., McCarthy, H., Li, J., Simpson, D., Offner, F., Moreno, C., Dai, S., Szoke, A., Dean, J. P., Kipps, T. J., Ghia, P.

Get full text

A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome by Cools, Jan, DeAngelo, Daniel J, Gotlib, Jason, Stover, Elizabeth H, Legare, Robert D, Cortes, Jorges, Kutok, Jeffrey, Clark, Jennifer, Galinsky, Ilene, Griffin, James D, Cross, Nicholas C.P, Tefferi, Ayalew, Malone, James, Alam, Rafeul, Schrier, Stanley L, Schmid, Janet, Rose, Michal, Vandenberghe, Peter, Verhoef, Gregor, Boogaerts, Marc, Wlodarska, Iwona, Kantarjian, Hagop, Marynen, Peter, Coutre, Steven E, Stone, Richard, Gilliland, D. Gary

“…A fusion between the PDGFRA and FIP1L1 genes was found in some cases of the hypereosinophilic syndrome, a fatal disorder in which eosinophils invade and…”
Get full text

NCCN Practice Guidelines for Acute Myelogenous Leukemia by Appelbaum, F R, Baer, M R, Carabasi, M H, Coutre, S E, Erba, H P, Estey, E, Glenn, M J, Kraut, E H, Maslak, P, Millenson, M, Miller, C B, Saba, H I, Stone, R, Tallman, M S

Get more information

Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass by DeAnda, Abe, Coutre, Steven E., Moon, Marc R., Vial, Conrad M., Griffin, Linda C., Law, Veronica S., Komeda, Masashi, Leung, Lawrence L.K., Miller, D.Craig

“…Heparin is normally used for anticoagulation during cardiopulmonary bypass (CPB), but its use is contraindicated in patients with a history of heparin-induced…”
Get full text

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study by O'Brien, Susan, Prof, Jones, Jeffrey A, MD, Coutre, Steven E, Prof, Mato, Anthony R, MD, Hillmen, Peter, Prof, Tam, Constantine, MD, Österborg, Anders, Prof, Siddiqi, Tanya, MD, Thirman, Michael J, MD, Furman, Richard R, MD, Ilhan, Osman, Prof, Keating, Michael J, Prof, Call, Timothy G, MD, Brown, Jennifer R, MD, Stevens-Brogan, Michelle, MSc, Li, Yunfeng, PhD, Clow, Fong, ScD, James, Danelle F, MD, Chu, Alvina D, MD, Hallek, Michael, Prof, Stilgenbauer, Stephan, Prof

“…Summary Background The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 17 (17p). Patients with 17p deletion…”
Get full text

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia by LIEDTKE, Michaela, TWIST, Clare J, MEDEIROS, Bruno C, GOTLIB, Jason R, BERUBE, Caroline, BIEBER, Marcia M, BHAT, Neelima M, TENG, Nelson N, COUTRE, Steven E

“…This phase I trial was conducted to determine the safety and pharmacokinetics of monoclonal antibody 216, a human monoclonal Immunoglobulin M antibody…”
Get full text

Vincristine sulfate liposomes injection (VSLI) “bridging” to potentially curative hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) by Schiller, G. J., Coutre, S. E., Larson, M. L., Ben Yehuda, D., Venugopal, P., Goldberg, S., Messerschmidt, G. L., Silverman, J., Deitcher, S. R., Kantarjian, H.

“…Abstract only…”
Get full text

Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study by Pollyea, D. A., Kohrt, H. E., Gallegos, L., Zhang, B., Figueroa, M., Melnick, A., Berube, C., Coutre, S. E., Gotlib, J. R., Zehnder, J. L., Liedtke, M., Mitchell, B. S., Medeiros, B. C.

“…Abstract only…”
Get full text

A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies by Flinn, I. W., Schreeder, M. T., Coutre, S. E., Leonard, J., Wagner-Johnston, N. D., De Vos, S., Boccia, R. V., Holes, L., Peterman, S., Miller, L. L., Yu, A. S.

“…Abstract only…”
Get full text

Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL by Shepard, D. D., Kohrt, H. E., Rosenblat, T. L., Jurcic, J. G., Park, J. H., Goldman, A., Dalal, J. S., Maslak, P. G., Jakubowski, A. A., Klimek, V., Berman, E., Nand, S., Coutre, S. E., Tallman, M. S., Erba, H. P.

“…Abstract only…”
Get full text

An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients by Pollyea, D. A., Kohrt, H. E., Rajwanshi, R., Gallegos, L., Berube, C., Coutre, S. E., Gotlib, J. R., Liedtke, M., Mitchell, B. S., Medeiros, B. C.

“…Abstract only…”
Get full text

Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia by Kreitman, R. J., Tallman, M. S., Coutre, S. E., Robak, T., Wilson, W. H., Stetler-Stevenson, M., Noel, P., FitzGerald, D. J., McDevitt, J. T., Pastan, I.

“…Abstract only…”
Get full text

PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM) by Alsina, M., Lonial, S., Weber, D. M., Coutre, S. E., Kang, B. P., Glynos, T., Warsi, G., Snodgrass, S. M., Richardson, P. G.

“…Abstract only…”
Get full text

Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia by Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., Rajwanshi, R., Zehnder, J.

“…Abstract only 7052 Background: High treatment-related mortality and low response rates often discourage elderly patients with acute myeloid leukemia from…”
Get full text

Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study by Byrd, J. C., Blum, K. A., Burger, J. A., Coutre, S. E., Sharman, J. P., Furman, R. R., Flinn, I. W., Grant, B. W., Richards, D. A., Zhao, W., Heerema, N. A., Johnson, A. J., Izumi, R., Hamdy, A., O'Brien, S. M.

“…Abstract only…”
Get full text

Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia by Coutre, S. E., Byrd, J. C., Furman, R. R., Brown, J. R., Benson, D. M., Wagner-Johnston, N. D., Flinn, I. W., Kahl, B. S., Spurgeon, S. E. F., Lannutti, B. J., Hsu, H. K. W., Ulrich, R., Peterman, S., Holes, L., Miller, L. L., Yu, A. S.

“…Abstract only…”
Get full text